Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology

Haematologica

Volumn 94, Issue 1, 2009, Pages 113-122

  Cornely, Oliver A ^a   Böhme, Angelika ^b   Buchheidt, Dieter ^c   Einsele, Hermann ^d   Heinz, Werner J ^d   Karthaus, Meinolf ^e   Krause, Stefan W ^f   Krüger, William ^g   Maschmeyer, Georg ^h   Penack, Olaf ⁱ   Ritter, Jörg ^j   Ruhnke, Markus ⁱ   Sandherr, Michael ^k   Sieniawski, Michal ^l   Vehreschild, Jörg Janne ^a   Wolf, Hans Heinrich ^m   Ullmann, Andrew J ⁿ  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b Onkologikum Frankfurt Am Museumsufer   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^e Klinikum Neuperlach   (Germany)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^g UNIVERSITY OF GREIFSWALD   (Germany)

^h KLINIKUM ERNST VON BERGMANN   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^k Schwerpunktpraxis für Hämatologie und Onkologie   (Germany)

^l NEWCASTLE UNIVERSITY   (United Kingdom)

^m MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

ⁿ JOHANNES GUTENBERG UNIVERSITY   (Germany)

more..

Author keywords

Amphotericin B; Antifungal prophylaxis; Fluconazole; Invasive fungal infection; Itraconazole; Liposomal; Posaconazole

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CLOTRIMAZOLE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; NYSTATIN; PLACEBO; POSACONAZOLE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; CANDIDA KRUSEI; CLINICAL TRIAL; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; LUNG ASPERGILLOSIS; MORTALITY; MUCORMYCOSIS; MYCOSIS; PROPHYLAXIS; REVIEW;

EID: 58149234268     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11665     Document Type: Review

References (115)

1. Pfaffenbach B, Donhuijsen K, Pahnke J, Bug R, Adamek RJ, Wegener M, et al. [Systemic fungal infections in hematologic neoplasms. An autopsy study of 1,053 patients]. Med Klin 1994;89:299-304.
2. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the post-mortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996;33:23-32.
3. Bodey G, Bueltmann B, Duguid W, Gibbs D, Hanak H, Hotchi M, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992;11:99-109.
4. Rex JH, Sobel JD. Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001;32:1191-200.
5. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29:239-44.
6. Ullmann AJ. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr Med Res Opin 2003;19:263-71.
7. Raad, II, Graybill JR, Bustamante AB, Cornely OA, Gaona-Flores V, Afif C, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006;42:1726-34.
8. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
9. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44:2-12.
10. Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007;44:373-9.
11. von Eiff M, Roos N, Schulten R, Hesse M, Zuhlsdorf M, van de Loo J. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 1995;62:341-7.
12. Cornely OA, Böhme A, Buchheidt D, Glasmacher A, Kahl C, Karthaus M, et al. Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003;82(Suppl 2):S186-200.
13. Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 2005;131:22-8.
14. Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007;25:5471-89.
15. Kish MA. Guide to development of practice guidelines. Clin Infect Dis 2001;32:851-4.
16. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
17. Philpott-Howard JN, Wade JJ, Mufti GJ, Brammer KW, Ehninger G. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. J Antimicrob Chemother 1993;31:973-84.
18. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-52.
19. Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers ME, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: longterm follow-up of a randomized, placebo-controlled trial. Blood 2000;96:2055-61.
20. Upton A, McCune JS, Kirby KA, Leisenring W, McDonald G, Batchelder A, et al. Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007;13:760-4.
21. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999;28:331-40.
22. Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 1995;172:1035-41.
23. Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993;118:495-503.
24. Young GA, Bosly A, Gibbs DL, Durrant S. A double-blind comparison of fluconazole and nystatin in the prevention of candidiasis in patients with leukaemia. Antifungal Prophylaxis Study Group. Eur J Cancer 1999;35:1208-13.
25. Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, D'Antonio D, et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. The GIMEMA Infection Program. Ann Intern Med 1994;120:913-8.
26. Morgenstern GR, Prentice AG, Prentice HG, Ropner JE, Schey SA, Warnock DW. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 1999;105:901-11.
27. Huijgens PC, Simoons-Smit AM, van Loenen AC, Prooy E, van Tinteren H, Ossenkoppele GJ, et al. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. J Clin Pathol 1999;52:376-80.
28. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59.
29. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-47.
30. Abbas J, Bodey GP, Hanna HA, Mardani M, Girgawy E, Abi-Said D, et al. Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch Intern Med 2000;160:2659-64.
31. Laverdiere M, Rotstein C, Bow EJ, Roberts RS, Ioannou S, Carr D, et al. Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study. J Antimicrob Chemother 2000;46:1001-8.
32. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002;35:627-30.
33. Nucci M, Biasoli I, Akiti T, Silveira F, Solza C, Barreiros G, et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 2000;30:300-5.
34. Glasmacher A, Hahn C, Molitor E, Marklein G, Sauerbruch T, Schmidt-Wolf IG. Itraconazole through concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses 1999;42:591-600.
35. Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, Girmenia C, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell'Adulto. Clin Infect Dis 1999;28:250-5.
36. Boogaerts M, Maertens J, van Hoof A, de Bock R, Fillet G, Peetermans M, et al. Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. J Antimicrob Chemother 2001;48:97-103.
37. Glasmacher A, Cornely O, Ullmann AJ, Wedding U, Bodenstein H, Wandt H, et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 2006;57:317-25.
38. Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003;138:705-13.
39. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103:1527-33.
40. Marr KA, Leisenring W, Crippa F, Slattery JT, Corey L, Boeckh M, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004;103:1557-9.
41. Glasmacher A, Prentice A, Gorschluter M, Engelhart S, Hahn C, Djulbegovic B, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003;21:4615-26.
42. Glasmacher A, Molitor E, Hahn C, Bomba K, Ewig S, Leutner C, et al. Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Leukemia 1998;12:1338-43.
43. Caillot D, Bassaris H, McGeer A, Arthur C, Prentice HG, Seifert W, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001;33:e83-90.
44. Sandherr M, Vogeser M, Hartwig C, Aulmann C, Fuhrmann S, Wondzinski L, et al. Antifungal prophylaxis with itraconazole in patients with acute leukemia and after stem cell transplantation. 46th Annual Meeting of the American Society of Hematology; 2004 December 4-7, 2004; San Diego, CA, USA. 2004.
45. Vehreschild JJ, Bohme A, Buchheidt D, Arenz D, Harnischmacher U, Heussel CP, et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 2007;55:445-9.
46. Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Gersten ID, et al. Results of a Randomized, Double-Blind trial of Fluconazole vs. Voriconazole for the prevention of invasive fungal infections in 600 allogeneic blood and marrow transplant patients. Blood 2007;110: [Abstract #163].
47. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004;350:950-2.
48. Glöckner A, Vehreschild JJ, Cornely OA. Zygomycosis - current epidemiological aspects. Mycoses 2007;50 (Suppl 1):50-5.
49. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005;191:1350-9.
50. Brincker H. Prevention of mycosis in granulocytopenic patients with prophylactic ketoconazole treatment. Mykosen 1983;26:242-7.
51. Donnelly JP, Starke ID, Galton DA, Catovsky D, Goldman JM, Darrell JH. Oral ketoconazole and amphotericin B for the prevention of yeast colonization in patients with acute leukaemia. J Hosp Infect 1984;5:83-91.
52. Estey E, Maksymiuk A, Smith T, Fainstein V, Keating M, McCredie KB, et al. Infection prophylaxis in acute leukemia. Comparative effectiveness of sulfamethoxazole and trimethoprim, ketoconazole, and a combination of the two. Arch Intern Med 1984;144:1562-8.
53. Hann IM, Prentice HG, Corringham R, Blacklock HA, Keaney M, Shannon M, et al. Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients. Lancet 1982;1:826-9.
54. Hansen RM, Reinerio N, Sohnle PG, Abrams RA, Ritch PS, Libnoch JA, et al. Ketoconazole in the prevention of candidiasis in patients with cancer. A prospective, randomized, controlled, double-blind study. Arch Intern Med 1987;147:710-2.
55. Jones PG, Kauffman CA, McAuliffe LS, Liepman MK, Bergman AG. Efficacy of ketoconazole vs nystatin in prevention of fungal infections in neutropenic patients. Arch Intern Med 1984;144:549-51.
56. Shepp DH, Klosterman A, Siegel MS, Meyers JD. Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment. J Infect Dis 1985;152:1257-63.
57. Vogler WR, Malcom LG, Winton EF. A randomized trial comparing ketoconazole and nystatin prophylactic therapy in neutropenic patients. Cancer Invest 1987;5:267-73.
58. Palmblad J, Lonnqvist B, Carlsson B, Grimfors G, Jarnmark M, Lerner R, et al. Oral ketoconazole prophylaxis for Candida infections during induction therapy for acute leukaemia in adults: more bacteraemias. J Intern Med 1992;231:363-70.
59. Brincker H. Prophylactic treatment with miconazole in patients highly predisposed to fungal infection. A placebo-controlled double-blind study. Acta Med Scand 1978;204:123-8.
60. Egger T, Gratwohl A, Tichelli A, Uhr M, Stebler Gysi C, Passweg J, et al. Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients. A prospective, randomized, single-center study. Support Care Cancer 1995;3:139-46.
61. Ellis ME, Clink H, Ernst P, Halim MA, Padmos A, Spence D, et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 1994;13:3-11.
62. Rozenberg-Arska M, Dekker AW, Branger J, Verhoef J. A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia. J Antimicrob Chemother 1991;27:369-76.
63. Hertenstein B, Kern WV, Schmeiser T, Stefanic M, Bunjes D, Wiesneth M, et al. Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann Hematol 1994;68:21-6.
64. Erjavec Z, Woolthuis GM, de Vries-Hospers HG, Sluiter WJ, Daenen SM, de Pauw B, et al. Tolerance and efficacy of Amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Eur J Clin Microbiol Infect Dis 1997;16:364-8.
65. Schwartz S, Behre G, Heinemann V, Wandt H, Schilling E, Arning M, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999;93:3654-61.
66. Alexander BD, Dodds Ashley ES, Addison RM, Alspaugh JA, Chao NJ, Perfect JR. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2006;8:13-20.
67. Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduijn JK, Hop WC, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008;46:1401-8.
68. Perfect JR, Klotman ME, Gilbert CC, Crawford DD, Rosner GL, Wright KA, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992;165: 891-7.
69. Wolff SN, Fay J, Stevens D, Herzig RH, Pohlman B, Bolwell B, et al. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. Bone Marrow Transplant 2000;25:853-9.
70. Bodey GP, Anaissie EJ, Elting LS, Estey E, O'Brien S, Kantarjian H. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 1994;73:2099-106.
71. Karthaus M, Doellmann T, Klimasch T, Elser C, Rosenthal C, Ganser A, et al. Intensive intravenous amphotericin B for prophylaxis of systemic fungal infections. Results of a prospective controlled pilot study in acute leukemia patients. Chemotherapy 2000;46:293-302.
72. Böhme A, Hoelzer D. Primary anti-fungal prophylaxis with low-dose intravenous amphotericin B in hematological malignancies. Results of a pilot study. Onkologie 2000;23:145-50.
73. Arning M, Scharf RE. Prevention of amphotericin-B-induced nephrotoxicity by loading with sodium chloride: a report of 1291 days of treatment with amphotericin B without renal failure. Klin Wochenschr 1989;67:1020-8.
74. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001;32:686-93.
75. Ullmann AJ, Sanz MA, Tramarin A, Barnes RA, Wu W, Gerlach BA, et al. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 2006;43:e29-38.
76. Cornely OA, Vehreschild JJ, Ullmann AJ. Is there a role for polyenes in treating invasive mycoses? Curr Opin Infect Dis 2006;19:565-70.
77. BitMansour A, Brown JMY. Prophylactic administration of Liposomal amphotericin B is superior to treatment in a Murine Model of Invasive aspergillosis after hematopoietic cell transplantation. J Inf Dis 2002;186:134-7.
78. Tollemar J, Ringden O, Andersson S, Sundberg B, Ljungman P, Tyden G. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993;12:577-82.
79. Tollemar J, Ringden O, Andersson S, Sundberg B, Ljungman P, Sparrelid E, et al. Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipients. Transplant Proc 1993;25:1495-7.
80. Tollemar J, Hockerstedt K, Ericzon BG, Sundberg B, Ringden O. Fungal prophylaxis with AmBisome in liver and bone marrow transplant recipients: results of two randomized double-blind studies. Transplant Proc 1994;26:1833.
81. Kelsey SM, Goldman JM, McCann S, Newland AC, Scarffe JH, Oppenheim BA, et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999;23:163-8.
82. Penack O, Schwartz S, Martus P, Reinwald M, Schmidt-Hieber M, Thiel E, et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006;17:1306-12.
83. Cordonnier C, Mohty M, Faucher C, Pautas C, Robin M, Vey N, et al. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. Int J Antimicrob Agents 2008;31:135-41.
84. Timmers GJ, Zweegman S, Simoons-Smit AM, van Loenen AC, Touw D, Huijgens PC. Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. Bone Marrow Transplant 2000;25:879-84.
85. Gotzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients (Cochrane Review). Cochrane Database Syst Rev 2002: CD002033.
86. Buchanan AG, Riben PD, Rayner EN, Parker SE, Ronald AR, Louie TJ. Nystatin prophylaxis of fungal colonization and infection in granulocytopenic patients: correlation of colonization and clinical outcome. Clin Invest Med 1985;8:139-47.
87. Mattiuzzi GN, Alvarado G, Giles FJ, Ostrosky-Zeichner L, Cortes J, O'Brien S, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 2006;50:143-7.
88. Cornely OA, Ullmann AJ, Karthaus M. Choosing a study population for the evaluation of antifungal prophylaxis. Clin Infect Dis 2005;40:1699-701.
89. van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, et al. Micafungin versus Fluconazole for prophylaxis against invasive fungal infections during Neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:1407-16.
90. Chandrasekar PH, Gatny CM. Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients. Bone Marrow Transplantation Team. Chemotherapy 1994;40:136-43.
91. MacMillan ML, Goodman JL, DeFor TE, Weisdorf DJ. Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. Am J Med 2002;112:369-79.
92. Oren I, Rowe JM, Sprecher H, Tamir A, Benyamini N, Akria L, et al. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2006;38:127-34.
93. Mattiuzzi GN, Estey E, Raad I, Giles F, Cortes J, Shen Y, et al. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 2003;97:450-6.
94. Yamac K, Senol E, Haznedar R. Prophylactic use of fluconazole in neutropenic cancer patients. Postgrad Med J 1995;71:284-6.
95. Kern W, Behre G, Rudolf T, Kerkhoff A, Grote-Metke A, Eimermacher H, et al. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group. Cancer 1998;83:291-301.
96. Hashino S, Morita L, Takahata M, Onozawa M, Nakagawa M, Kawamura T, et al. Administration of micafungin as prophylactic anti-fungal therapy in patients undergoing allogeneic stem cell transplantation. Int J Hematol 2008;87:91-7.
97. Annaloro C, Oriana A, Tagliaferri E, Bertolli V, Della Volpe A, Soligo D, et al. Efficacy of different prophylactic antifungal regimens in bone marrow transplantation. Haematologica 1995;80:512-7.
98. Ito Y, Ohyashiki K, Yoshida I, Takeuchi M, Aoyama Y, Mugitani A, et al. The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes: a Japanese multicenter randomized, controlled study. Int J Hematol 2007;85:121-7.
99. Akiyama H, Mori S, Tanikawa S, Sakamaki H, Onozawa Y. Fluconazole versus oral amphotericin B in preventing fungal infection in chemotherapy-induced neutropenic patients with haematological malignancies. Mycoses 1993;36:373-8.
100. Meunier F, Aoun M, Janssens M, Dekoster C, Paesmans M. Chemoprophylaxis of fungal infections in granulocytopenic patients using fluconazole vs oral amphotericin B. Drug Invest 1991;3:258-65.
101. Takatsuka H, Takemoto Y, Okamoto T, Fujimori Y, Tamura S, Wada H, et al. Fluconazole versus amphotericin B for the prevention of fungal infection in neutropenic patients with hematologic malignancy. Drugs Exp Clin Res 1999;25: 193-200.
102. Ninane J. A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre Study Group. Eur J Clin Microbiol Infect Dis 1994;13:330-7.
103. Groll AH, Just-Nuebling G, Kurz M, Mueller C, Nowak-Goettl U, Schwabe D, et al. Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer. J Antimicrob Chemother 1997;40:855-62.
104. Alangaden G, Chandrasekar PH, Bailey E, Khaliq Y. Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. The Bone Marrow Transplantation Team. Bone Marrow Transplant 1994;14:919-24.
105. Brammer KW. Management of fungal infection in neutropenic patients with fluconazole. Haematology and Blood Transfusion 1990;33:546-50.
106. Finke R. Comparison of oral fluconazole and amphotericin B prophylaxis against fungal infections in the neutropenic phase of patients treated with antileukemic agents. Mycoses 1990;33 (Suppl 1):42-54.
107. Lass-Flörl C, Gunsilius E, Gastl G, Englisch M, Koch G, Ulmer H, et al. Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution. Ann Hematol 2003;82:565-9.
108. Harousseau JL, Dekker AW, Stamatoullas-Bastard A, Fassas A, Linkesch W, Gouveia J, et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 2000;44:1887-93.
109. Kaptan K, Ural AU, Cetin T, Avcu F, Beyan C, Yalcin A. Itraconazole is not effective for the prophylaxis of fungal infections in patients with neutropenia. J Infect Chemother 2003;9:40-5.
110. Vreugdenhil G, Van Dijke BJ, Donnelly JP, Novakova IR, Raemaekers JM, Hoogkamp-Korstanje MA, et al. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk Lymphoma 1993;11:353-8.
111. Böhme A, Just-Nübling G, Bergmann L, Shah PM, Stille W, Hoelzer D. Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. J Antimicrob Chemother 1996;38:953-61.
112. Thunnissen PL, Sizoo W, Hendriks WD. Safety and efficacy of itraconazole in prevention of fungal infections in neutropenic patients. Neth J Med 1991;39:84-91.
113. Tricot G, Joosten E, Boogaerts MA, Vande Pitte J, Cauwenbergh G. Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Rev Infect Dis 1987;9(Suppl 1):S94-9.
114. Lamy T, Bernard M, Courtois A, Jacquelinet C, Chevrier S, Dauriac C, et al. Prophylactic use of itraconazole for the prevention of invasive pulmonary aspergillosis in high risk neutropenic patients. Leuk Lymphoma 1998;30:163-74.
115. Todeschini G, Murari C, Bonesi R, Pizzolo G, Amaddi G, Ambrosetti A, et al. Oral itraconazole plus nasal amphotericin B for prophylaxis of invasive aspergillosis in patients with hematological malignancies. Eur J Clin Microbiol Infect Dis 1993;12:614-8.